CSL Limited
(ASX:CSL) has announced the European Commission has granted marketing approval for its haemophilia A treatment AFSTYLA®.
The treatment is the first and only single-chain product for hemophilia A and can be used for all age groups.
The product will be launched in European markets in the coming months as access is obtained.
AFSTYLA is now approved in the EU, the US and Canada with Switzerland and Australia currently reviewing marketing applications.
CSL Limited reported a net profit of $1.67 billion dollars at 30 June 2016.
